U.S. markets close in 3 hours 16 minutes
  • S&P 500

    3,265.88
    +19.29 (+0.59%)
     
  • Dow 30

    26,915.20
    +99.76 (+0.37%)
     
  • Nasdaq

    10,791.65
    +119.39 (+1.12%)
     
  • Russell 2000

    1,460.98
    +9.16 (+0.63%)
     
  • Crude Oil

    40.10
    -0.21 (-0.52%)
     
  • Gold

    1,863.30
    -13.60 (-0.72%)
     
  • Silver

    22.98
    -0.22 (-0.95%)
     
  • EUR/USD

    1.1628
    -0.0048 (-0.41%)
     
  • 10-Yr Bond

    0.6530
    -0.0130 (-1.95%)
     
  • GBP/USD

    1.2707
    -0.0045 (-0.35%)
     
  • USD/JPY

    105.5820
    +0.1800 (+0.17%)
     
  • BTC-USD

    10,648.20
    -112.39 (-1.04%)
     
  • CMC Crypto 200

    217.77
    -0.06 (-0.03%)
     
  • FTSE 100

    5,842.67
    +19.89 (+0.34%)
     
  • Nikkei 225

    23,204.62
    +116.80 (+0.51%)
     

Benzinga's Top Upgrades, Downgrades For July 27, 2020

Benzinga Insights
  • For First Community Corp (NASDAQ: FCCO), Raymond James upgraded the previous rating of Market Perform to the current rating Outperform. In the second quarter, First Community showed an EPS of $0.30, compared to $0.37 from the year-ago quarter. At the moment, the stock has a 52-week-high of $22.00 and a 52-week-low of $12.51. First Community closed at $13.66 at the end of the last trading period.

  • Raymond James upgraded American Airlines Group (NASDAQ:AAL) from Underperform to Market Perform. American Airlines shares closed at $11.39 on Friday.

  • Goldman Sachs upgraded Tapestry (NYSE:TPR) from Neutral to Buy. Tapestry shares closed at $13.47 on Friday.

  • Citigroup upgraded the previous rating for Schlumberger Ltd (NYSE: SLB) from Neutral to Buy. For the second quarter, Schlumberger had an EPS of $0.05, compared to year-ago quarter EPS of $0.35. The stock has a 52-week-high of $41.14 and a 52-week-low of $11.87. At the end of the last trading period, Schlumberger closed at $19.49.

 

  • Credit Suisse downgraded Archer-Daniels Midland (NYSE: ADM) from Neutral to Underperform. Archer-Daniels Midland shares closed at $42.09 on Friday.

  • Berenberg downgraded Albemarle (NYSE:ALB) from Hold to Sell. Albemarle sharse closed at $87.04 on Friday.

  • JP Morgan downgraded Cabot Corporation (NYSE:CBT) from Overweight to Neutral. Cabot shares closed at $38.25 on Friday.

  • Roth Capital downgraded First Solar (NASDAQ:FSLR) from Buy to Neutral. First Solar shares closed at $62.16 on Friday.

 

  • Deutsche Bank initiated coverage on Dun & Bradstreet Holdings Inc (NYSE: DNB) with a Buy rating. The price target for Dun & Bradstreet Holdings is set to $30.00. For the third quarter, Dun & Bradstreet Holdings had an EPS of $1.85, compared to year-ago quarter EPS of $1.79. Moreover, at the end of the last trading period, the closing price was at $25.12.

  • Credit Suisse initiated coverage on Accolade Inc (NASDAQ: ACCD) with a Neutral rating. The price target for Accolade is set to $38.00. Moreover, at the end of the last trading period, the closing price was at $32.94.

  • Raymond James initiated coverage on Oshkosh Corp (NYSE: OSK) with an Outperform rating. The price target for Oshkosh is set to $85.00. Oshkosh earned $1.25 in the second quarter, compared to $1.82 in the year-ago quarter. At the moment, the stock has a 52-week-high of $95.62 and a 52-week-low of $46.72. Oshkosh closed at $78.58 at the end of the last trading period.

  • HC Wainwright & Co. initiated coverage on Meridian Bioscience Inc (NASDAQ: VIVO) with a Buy rating. The price target for Meridian Bioscience is set to $34.00. In the second quarter, Meridian Bioscience showed an EPS of $0.23, compared to $0.19 from the year-ago quarter. At the moment, the stock has a 52-week-high of $25.88 and a 52-week-low of $5.51. Meridian Bioscience closed at $23.15 at the end of the last trading period.

  • With a current rating of Buy, HC Wainwright & Co. initiated coverage on Satsuma Pharmaceuticals Inc (NASDAQ: STSA). The price target seems to have been set at $35.00 for Satsuma Pharmaceuticals. Satsuma Pharmaceuticals earned ($0.68) in the first quarter, compared to ($2.51) in the year-ago quarter. At the moment, the stock has a 52-week-high of $36.10 and a 52-week-low of $8.61. Satsuma Pharmaceuticals closed at $25.63 at the end of the last trading period.

See more from Benzinga


© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.